Mangalam Drugs and Organics Ltd
MANGALAM NSE
Mangalam Drugs and Organics Ltd
HealthcareNSE: MANGALAM BSE: 532637 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹43.37 Cr
Volatility
Moderate
P/E Ratio
-1
EBITDA
₹-14.91 Cr
Return on Equity
4.51%
Debt to Equity
1.02
Book Value
₹60.64
52W High
₹89.84
52W Low
₹22.8
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Mangalam Drugs and Organics Ltd insights
45 extracted metrics + investor summaries across FY12–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
1- Stock is trading at 0.42 times its book value
Weaknesses
7- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -9.39% over past five years.
- Promoter holding is low: 35.6%
- Company has a low return on equity of -11.0% over last 3 years.
- Contingent liabilities of Rs.34.6 Cr.
- Debtor days have increased from 45.3 to 63.4 days.
- Promoter holding has decreased over last 3 years: -14.7%
Growth Rate
Revenue Growth
-27.16% ↘
Net Income Growth
-829.25% ↘
Cash Flow Change
989.26% ↗
ROE
-167.51% ↘
ROCE
571.43% ↗
EBITDA Margin (Avg.)
-156.14% ↗
Quarterly Results
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 91 | 87 | 82 | 97 | 102 | 77 | 80 | 89 | 73 | 57 | 50 | 58 | 67 |
| Expenses | 91 | 91 | 79 | 90 | 91 | 68 | 71 | 80 | 63 | 62 | 52 | 60 | 73 |
| Operating Profit | 0 | -3 | 2 | 7 | 12 | 8 | 9 | 9 | 10 | -5 | -3 | -2 | -5 |
| OPM % | 0.3% | -4% | 2.7% | 7% | 11% | 11% | 11% | 10% | 14% | -8% | -6% | -2.7% | -8% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 3 | 4 | 4 | 5 | 4 | 3 |
| Depreciation | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 4 | 5 | 4 | 5 |
| PBT | -6 | -10 | -5 | 0 | 4 | 1 | 1 | 1 | 2 | -13 | -12 | -10 | -13 |
| Tax % | -22% | -7% | -25% | -920% | 10% | -356% | -125% | 5% | 91% | 6% | -41% | 0% | 1% |
| Net Profit | -4 | -10 | -4 | 0 | 4 | 3 | 3 | 1 | 0 | -14 | -7 | -10 | -13 |
| EPS in Rs | -2.77 | -6.03 | -2.25 | 0.32 | 2.24 | 1.69 | 1.7 | 0.88 | 0.09 | -8.67 | -4.58 | -6.18 | -8.25 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 221 | 295 | 299 | 269 | 228 | 282 | 380 | 451 | 372 | 369 | 318 | 232 |
| Expenses | 200 | 257 | 252 | 222 | 218 | 259 | 327 | 402 | 347 | 351 | 282 | 247 |
| Operating Profit | 20 | 38 | 47 | 47 | 10 | 24 | 53 | 49 | 26 | 17 | 36 | -15 |
| OPM % | 9% | 13% | 16% | 17% | 4.3% | 8% | 14% | 11% | 7% | 4.7% | 11% | -6% |
| Other Income | 0 | 0 | 0 | 1 | 0 | 1 | 5 | 0 | 0 | 0 | 0 | 1 |
| Interest | 10 | 9 | 10 | 12 | 9 | 10 | 9 | 11 | 13 | 14 | 15 | 16 |
| Depreciation | 4 | 4 | 5 | 7 | 7 | 8 | 9 | 10 | 11 | 15 | 16 | 18 |
| PBT | 6 | 24 | 31 | 29 | -6 | 6 | 40 | 28 | 2 | -11 | 5 | -48 |
| Tax % | -2% | 33% | 29% | 32% | 40% | -32% | 29% | 29% | 43% | -18% | -39% | -9% |
| Net Profit | 6 | 16 | 22 | 20 | -8 | 8 | 28 | 20 | 1 | -9 | 7 | -44 |
| EPS in Rs | 4.66 | 11.15 | 14.08 | 12.57 | -5.07 | 5.21 | 17.67 | 12.42 | 0.8 | -5.72 | 4.37 | -27.68 |
| Div. Payout % | 0% | 0% | 0% | 4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 14 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 16 | 47 | 70 | 88 | 80 | 88 | 115 | 135 | 136 | 127 | 133 | 87 |
| Borrowings | 78 | 60 | 66 | 69 | 65 | 52 | 70 | 88 | 89 | 107 | 96 | 105 |
| Other Liabilities | 63 | 38 | 38 | 54 | 50 | 75 | 64 | 90 | 117 | 108 | 114 | 99 |
| Total Liabilities | 170 | 160 | 190 | 227 | 211 | 231 | 264 | 328 | 358 | 357 | 359 | 308 |
| Fixed Assets | 53 | 54 | 93 | 102 | 103 | 101 | 118 | 135 | 142 | 147 | 156 | 152 |
| CWIP | 0 | 5 | 0 | 0 | 0 | 1 | 6 | 6 | 9 | 8 | 3 | 0 |
| Investments | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 117 | 100 | 95 | 125 | 107 | 128 | 140 | 188 | 206 | 202 | 201 | 156 |
| Total Assets | 170 | 160 | 190 | 227 | 211 | 231 | 264 | 328 | 358 | 357 | 359 | 308 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 14 | 22 | 43 | 25 | 22 | 31 | 28 | 26 | 38 | 12 | 43 | 4 |
| Investing | -4 | -11 | -39 | -16 | -9 | -7 | -31 | -27 | -22 | -18 | -19 | -12 |
| Financing | -10 | -11 | -3 | -9 | -11 | -23 | 3 | 3 | -17 | 6 | -22 | 6 |
| Net Cash Flow | 1 | 0 | 0 | 0 | 1 | 0 | -1 | 1 | -1 | 0 | 2 | -2 |
| Free Cash Flow | 10 | 11 | 3 | 9 | 12 | 24 | -4 | -2 | 16 | -6 | 23 | -8 |
| CFO/OP | 69 | 68 | 107 | 66 | 223 | 129 | 69 | 70 | 148 | 71 | 119 | -30 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 73 | 37 | 45 | 61 | 28 | 52 | 52 | 38 | 46 | 28 | 45 | 63 |
| Inventory Days | 134 | 85 | 69 | 132 | 175 | 121 | 85 | 139 | 200 | 185 | 303 | 239 |
| Days Payable | 128 | 37 | 38 | 82 | 77 | 106 | 63 | 65 | 139 | 124 | 199 | 160 |
| Cash Conversion Cycle | 79 | 85 | 75 | 111 | 126 | 67 | 74 | 112 | 107 | 88 | 148 | 142 |
| Working Capital Days | 26 | 32 | 19 | 31 | 21 | 10 | 23 | 43 | 38 | 18 | 13 | -54 |
| ROCE % | 16% | 29% | 31% | 25% | 2% | 11% | 27% | 18% | 6% | 1% | 8% | -14% |
Documents
4
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 14Th May, 2026 Inter-Alia To Approve Audited Financial Results(Standalone & Consolidated) Of The Company For The Period Ended 31St March, 2026
6 May - Board meeting on May 14, 2026 to approve audited Q4 and FY26 results; trading window closed from April 1. 6 May - Board meeting on May 14, 2026 to approve audited Q4 and FY26 results; trading window closed from April 1.
Frequently Asked Questions about Mangalam Drugs and Organics Ltd
What does Mangalam Drugs and Organics Ltd do?
Incorporated in 1977, Mangalam Drugs & Organics Ltd manufactures Active Pharmaceutical Ingredients and Intermediates.[1]
Where is Mangalam Drugs and Organics Ltd (MANGALAM) listed?
Mangalam Drugs and Organics Ltd is listed on the Indian stock exchanges. It is listed on NSE: MANGALAM and BSE: 532637. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Mangalam Drugs and Organics Ltd belong to?
Mangalam Drugs and Organics Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Mangalam Drugs and Organics Ltd?
Mangalam Drugs and Organics Ltd has a market capitalisation of approximately ₹43.37 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Mangalam Drugs and Organics Ltd?
The Price-to-Earnings (PE) ratio of Mangalam Drugs and Organics Ltd is -1.00. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Mangalam Drugs and Organics Ltd?
Over the past 52 weeks, Mangalam Drugs and Organics Ltd has traded between a low of ₹22.8 and a high of ₹89.84. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Mangalam Drugs and Organics Ltd?
Mangalam Drugs and Organics Ltd has a Return on Equity (ROE) of 4.51%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Mangalam Drugs and Organics Ltd on Tapetide?
On Tapetide, you can view Mangalam Drugs and Organics Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 1977, Mangalam Drugs & Organics Ltd manufactures Active Pharmaceutical Ingredients and Intermediates.[1]